Brittany Sexton, PhD
Research Awards Nationwide Recipient (2016-2017)
Massachusetts General Hospital
Funded by LUNG FORCE
Discovering Inner Workings of Enzyme Could Lead to Lung Cancer Treatment
Abnormal duplication of genes contributes to lung cancer risk and associated drug resistance. We will study the enzyme KDM4A, which is overexpressed (makes too many copies) in lung cancer, and leads to a higher frequency of copies of genetic regions linked to drug resistance and increased potential for the spread of lung cancer. KDM4A overexpression in cancer cells also results in reduced response to chemotherapy. We will determine the relationship between KDM4A expression levels, extra copies of drug resistant regions and their impact on drug resistance in lung cancer. These studies could lead to development of new treatments for lung cancer.